Imcivree (for rare genetic obesity)

Imcivree (setmelanotide) is an MC4R agonist specifically approved for chronic weight management in patients with rare genetic forms of obesity, such as POMC, PCSK1, or LEPR deficiency. By restoring signaling in the melanocortin-4 pathway, it addresses the root cause of excessive appetite and weight gain in these conditions. Imcivree is not indicated for general obesity management but provides a life-changing option for individuals with confirmed genetic diagnoses. Treatment is administered via injection, typically under the care of specialty centers. Common side effects include injection-site reactions, skin hyperpigmentation, nausea, and headache. Its availability is limited and highly regulated.

• Manufacturer: Rhythm Pharmaceuticals
• Primary Use: Genetic obesity (specified variants)
• Form: Injectable

Common Side Effects

The most common side effects of Imcivree (for rare genetic obesity) may include:

• Injection site reactions
• Skin hyperpigmentation
• Headache
• Nausea

This is not a complete list. Always consult with your healthcare provider about potential side effects.